ATHEROSCLEROTIC PROGRESSION/ REGRESSION

Atherosclerotic Progression/ Regression

Lp(a): Vascular Events by Sex and Quintile at Baseline (Cardiovascular Health Study)

CHARISMA: Clopidogrel + Aspirin vs Aspirin Alone in High-Risk CVD Patients

ASAP: Study Design

ASAP: Cholesterol-Lowering Results

ASAP: Primary Parameter Change in Overall Carotid IMT

EPAT: Baseline Characteristics of Evaluable Patients

EPAT: Progression of Carotid Artery Intima-Media Thickness (IMT)

DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes

ASTEROID: High-Dose Statin Therapy–Effects on Atherosclerosis

ASTEROID: High-Dose Statin Therapy—Effects on LDL-C and HDL-C

ASTEROID: High-Dose Statin Therapy—Effects on Discrete Coronary Stenoses

METEOR: Effects of Statin Therapy on Low-Risk Patients—Primary Endpoint

METEOR: Effects of Statin Therapy on Low-Risk Patients— Secondary Endpoints

ENHANCE: Combined Statin Therapy—Primary Outcome

ENHANCE: Combined Statin Therapy—Effects on Lipoproteins

LCAS: Effect on Lipids between Baseline and End of Trial

LCAS: Primary End Point

LCAS: Effect of Treatment on Patients Experiencing Progression or Regression

LCAS: Conclusions

L-CAD: Comparison of End Points, Change in Lumen Diameters

HATS: Lipid Levels Before and During Treatment

HATS: Percent Change in Stenosis

JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale

PDAY: Percentage of Right Coronary Artery Intimal Surface Affected With Early Atherosclerosis

PDAY: Prevalence of lesions in LAD

Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis

Post-CABG Study: Aggressive vs Moderate Treatment

Post-CABG: End Points, Results, Conclusions

Post-CABG Angiographic Outcomes

Post-CABG: Event Rates by Cholesterol Group

Post-CABG: Aggressive LDL-C Lowering Delays Progression of Atherosclerosis in Women, Elderly, and Patients With Selected CHD Risk Factors

PROactive: Time to Secondary Endpoint (Death, Nonfatal MI, Stroke)

REVERSAL: Effect of Moderate vs Intensive Statin Therapy

Post-CABG: Effect of Aggressive Lipid Lowering on a Subgroup of Patients With Diabetes

Effect of Lifestyle Changes on Angiographic CAD

Lp(a) in Atherogenesis: Another Culprit?

Homocysteine: Role of Atherogenesis

Continuum of Patients at Risk for a CHD Event

Coronary Artery Calcification (CAC) and CHD Family History

Ethnic Disparities in CVD Risk Factors in the US Population

US Death Rates From CVD by Ethnicity and Sex, 1980-2001

Smoking-Related CV Mortality in Year 2000

Trends in Total Cholesterol for US Adults, 1960-1962 to 1999-2002

WISE Study: Review of Ischemic Heart Disease in Women

Treatment Options for Peripheral Arterial Disease

Treatment Options for Peripheral Arterial Disease (cont)

Trans-Fatty Acid Intake and Relative Risk for CHD

4S: Effect of Cholesterol Lowering on Noncoronary Ischemic Symptoms and Angina

Lipid Lowering and Plaque Regression: Monotherapy Studies

Event Reduction in Angiographic Plaque Regression Trials

Endothelial Dysfunction: A Barometer of Cardiovascular Risk?

Association Between Change in Lumen Size and Coronary Events: Important Factors

Effects of Lipid-Lowering Therapy on Endothelial Function in CHD Patients

Effect of Cholesterol Lowering on Myocardial Ischemia

Atherosclerosis: A Progressive Process

The Anatomy of Atherosclerotic Plaque

Angiographically Inapparent Atheroma

The Matrix Skeleton of Unstable Coronary Artery Plaque

Histologic Stain of Plaque

Characteristics of Plaques Prone to Rupture

Updated Model of Lipoprotein Metabolism and Reverse Cholesterol Transport

TGs Predict CAD Risk Independently of TC and HDL-C

Hypertriglyceridemia and CHD Risk: Associated Abnormalities

Association of Small, Dense LDL With Myocardial Infarction

Responses to a 75-g Oral Glucose Challenge in Relation to LDL Particle Diameter

Characteristics of LDL Phenotype B

Cumulative Distribution of Adjusted Plasma TG Levels: LDL Phenotypes A and B

Cumulative Distribution of Adjusted HDL-C: LDL Phenotypes A and B

Interrelation Between Atherosclerosis and Insulin Resistance

Composite CIMT With Metabolic Syndrome in Young Adults

Progression to Atherosclerotic Clinical Events in Patients With Diabetes

Atherosclerosis in Diabetes

Insulin Resistance and Atherosclerosis: Posited Relationships

Significance of Small, Dense LDL

Effects of Atorvastatin on CRP and Endothelial Function in Type 2 Diabetes

Relation Between Change in CRP Endothelium-Dependent Vasodilation With Atorvastatin in Type 2 Diabetes (6 Months)

Effects of Lipid Lowering on Endothelial Function: Hypercholesterolemic Patients

Effects of Lipid-Lowering Therapy on Myocardial Perfusion in CHD Patients

Lowest Effective Aspirin Dose for MI and Stroke Reduction

Metabolic Syndrome and 10-Year CVD Risk

Potential Mechanisms of Atherogenesis in Diabetes

Impact of Statin-Induced Changes in LDL-C and HDL-C on Atheroma Burden (1 of 2)

Impact of Statin-Induced Changes in LDL-C and HDL-C on Atheroma Burden (2 of 2)

CLINICAL GUIDELINES

ATP III

ATP III: CHD Risk Equivalents

SEACOAST: Combination Therapy for Increased Non–HDL-C Primary Endpoint

ATP III: Features Shared With ATP II

ATP III: LDL-C, HDL-C, TC Classification

ATP III: Major CHD Risk Factors Other Than LDL-C

ATP III: Additional CHD Risk Factors

ATP III: Assessment of Risk

ATP III: Risk Categories, LDL-C Goals

ATP III: CHD Risk Equivalents

ATP III: LDL-C Treatment Cutpoints for Therapy

ATP III: Nutritional Components of the TLC Diet

ATP III: Additional Dietary Options for LDL-C Lowering

ATP III: Management of Elevated TG

ATP III: The Metabolic Syndrome

ATP III: Management of Diabetic Dyslipidemia

ATP III: LDL-C Measurements in Patients Hospitalized for Major Coronary Events

ATP III: Special Populations—Women, Middle-Aged Men

ATP III: Improving Adherence—Focus on the Patient

ATP III: Improving Adherence—Focus on the Physician, Delivery System

ATP III Framingham Risk Scoring–Assessing CHD Risk in Men

ATP III Framingham Risk Scoring–Assessing CHD Risk in Women

ATP III Framingham Risk Scoring–Step 1: Age

ATP III Framingham Risk Scoring–Step 2: Total Cholesterol

ATP III Framingham Risk Scoring–Step 3: HDL-Cholesterol

ATP III Framingham Risk Scoring–Step 4: Systolic Blood Pressure

ATP III Framingham Risk Scoring–Step 5: Smoking Status

ATP III Framingham Risk Scoring Step 6: Adding Up the Points (Sum From Steps 1–5)

ATP III Framingham Risk Scoring–Step 7: CHD Risk for Women

ATP III Framingham Risk Scoring Step 7: CHD Risk for Men

Update to ATP III Guidelines: Rationale

Update to ATP III Guidelines: Rationale (cont'd)

ATP III: Updated LDL-C Goals, Treatment Cutpoints

ATP III: Updated LDL-C Goals, Treatment Cutpoints (cont'd)

Eligible Primary-Prevention Patients by Age and Treatment Scenario (ATP III vs ATP II)

ATP III: Management of Very High LDL-C

ATP III: Management of Low HDL-C

ATP III: Special Populations—Older Adults, Younger Adults

ATP III vs ATP II: Increases in Treatment-Eligible Primary-Prevention Patients

Other

AHA Evidence-Based Guidelines for CVD Prevention in Women (cont'd)

Cost of CHD in the United States

Cost of CVD and Stroke in the United States

US Cost of Health Expenditures, Lost Productivity of CVD and Stroke

JNC 7: Treatment Algorithm for Hypertension

AHA/CDC Panel: Recommendations for Use of hs-CRP in Clinical Practice

AHA/CDC Panel: Recommendations for hs-CRP Laboratory Testing

Prevalence of Class 3 Obesity in the United States: BRFSS 2000

BMI: Adjusted Odds Ratios for Unstable Coronary Artery Disease

AHA Get With the Guidelines: Adherence to Treatment Measures

AHA Evidence-Based Guidelines for CVD Prevention in Women

CV Mortality Risk With NCEP-MetS vs WHO-MetS

Updated Criteria for Clinical Diagnosis of Metabolic Syndrome

Statin Advisory: Definitions of Muscle Toxicity

Statin Advisory: Monitoring Parameters, Follow-Up Schedule

Statin Advisory: Clinical Precautions When Prescribing Statin Therapy

Statin Advisory: Risk Factors for Statin-Associated Myopathy

Statin Advisory: Conclusions

ADA: Glycemic Control, BP, and Lipid Targets in Type 2 Diabetes

ADA: Treatment Decisions by LDL-C Levels in Adults With Type 2 Diabetes

CLINICAL TRIALS

A-F

Lp(a): An Independent CHD Risk Factor in Men of the Framingham Offspring Cohort

Lp(a): Vascular Events by Sex and Quintile at Baseline (Cardiovascular Health Study)

AFCAPS/TexCAPS: RR of Acute Coronary Events—LDL-C and Homocysteine

AFCAPS/TexCAPS: RR of Acute Coronary Events—TC: HDL-C Ratio and CRP Level

AFCAPS/TexCAPS: Effects of LDL C Lowering in Patients With Average Cholesterol Levels

ACCESS: Change in LDL-C, Non–HDL-C in All Patients at 54 Weeks

4S: Effect of LDL-C Lowering on Coronary Events in Secondary Prevention Trial in Men and Women

4S: Findings From a Post Hoc Analysis

4S: Lipid Lowering Reduces CHD Event Rates in >65-Year Old Subjects

4S: Impact of Drug Therapy on Lipids and Lipoproteins in Older Adults With Hypercholesterolemia

4S: Reduction in Coronary Events and Revascularizations in Older Adults With Established CHD

4S: Survival of Major Coronary Events in Older Adults

4S: Clinical and Economic Benefits of Treatment Over 5-Yr Period

CARE: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol

CARE: Fatal CHD or Nonfatal MI (Primary End Point)

CARE: Secondary End Points

CARE: Findings From a Post Hoc Analysis

CARE: Impact of Drug Therapy on Lipids and Lipoproteins in Older Patients With MI

CARE: Reduction in Coronary Events, Revascularizations, and Stroke in Older Adults With MI and Average Cholesterol Levels

CARE: Incidence of Coronary Events in Younger Versus Older Patients

AFCAPS/TexCAPS: Primary End Point Event Rates Within Demographic and Risk Factor Subgroups

A to Z Trial: Primary End Point

A to Z Trial: Secondary End Points and Adverse Events

CHARISMA: Clopidogrel + Aspirin vs Aspirin Alone in High-Risk CVD Patients

Impact of TG Levels on Relative Risk of CHD: Framingham Heart Study

Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes

Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year

Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes

Diabetes Prevention Program: Study Design